These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15965967)

  • 61. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
    J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.
    Kwak Y; Bohnen NI; Müller ML; Dayalu P; Burke DT; Seidler RD
    Behav Brain Res; 2013 May; 245():128-36. PubMed ID: 23439215
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
    Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
    Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
    De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
    Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
    Svetel M; Tomić A; Kresojević N; Kostić V
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
    Larsen JP; Worm-Petersen J; Sidén A; Gordin A; Reinikainen K; Leinonen M;
    Eur J Neurol; 2003 Mar; 10(2):137-46. PubMed ID: 12603288
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
    Vuletić V; Rački V; Papić E; Peterlin B
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281267
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
    Hu XW; Qin SM; Li D; Hu LF; Liu CF
    Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
    Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
    Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
    Yin Y; Liu Y; Xu M; Zhang X; Li C
    Neurol Sci; 2021 Oct; 42(10):4085-4094. PubMed ID: 34346015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.